Uptake, retention, and outcomes in a demonstration project of pre-exposure prophylaxis among female sex workers in public health centers in Senegal.
Adolescent
Adult
Anti-HIV Agents
/ administration & dosage
Feasibility Studies
Female
HIV Infections
/ epidemiology
Humans
Incidence
Medication Adherence
/ psychology
Middle Aged
Pre-Exposure Prophylaxis
/ methods
Program Evaluation
Retention in Care
/ statistics & numerical data
Senegal
/ epidemiology
Sex Workers
/ psychology
Africa
HIV
prevention
sex workers
women
Journal
International journal of STD & AIDS
ISSN: 1758-1052
Titre abrégé: Int J STD AIDS
Pays: England
ID NLM: 9007917
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
21
8
2020
medline:
22
6
2021
entrez:
22
8
2020
Statut:
ppublish
Résumé
The Senegal pre-exposure prophylaxis (PrEP) Demonstration Project was an open-label cohort study assessing the delivery of daily oral PrEP to HIV-negative female sex workers (FSWs) in four Ministry of Health (MoH)-run clinics in Dakar, Senegal. We assessed uptake, retention in care, and adherence over up to 12 months of follow-up as well as HIV infection rates. Between July and November 2015, 350 individuals were approached and 324 (92.6%) were preliminarily eligible. Uptake was high, with 82.4% of eligible participants choosing to enroll and take PrEP. The mean age of those enrolled was 37.7 years (SD = 8.7), and approximately half had not attended school (41.2%). Among the 267 participants who were prescribed PrEP, 79.9 and 73.4% were retained in PrEP care at 6 and 12 months, respectively. Older age among FSWs was found to be the only significant predictor of lower discontinuation. We did not find significant differences in retention by site, education, condom use, or HIV risk perception. There were no new HIV infections at follow-up. Our results showed evidence of high interest in PrEP and very good PrEP retention rates among FSWs at 12-month follow-up when offered in MoH-run clinics, with older age as the only significant predictor of higher PrEP retention. This highlights the role that these clinics can play in expanding PrEP access nationwide.
Identifiants
pubmed: 32819210
doi: 10.1177/0956462420943704
pmc: PMC7750667
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1063-1072Références
J Acquir Immune Defic Syndr. 2017 Sep 01;76(1):1-12
pubmed: 28291053
AIDS Res Hum Retroviruses. 2017 Mar 2;33(8):778-783
pubmed: 28253024
Gates Open Res. 2019 Jul 5;3:1504
pubmed: 31942537
AIDS. 2017 Jan 14;31(2):213-232
pubmed: 27831952
Sex Transm Infect. 2007 Dec;83(7):534-40
pubmed: 17942575
AIDS Behav. 2019 Jun;23(6):1494-1507
pubmed: 30788641
AIDS. 2019 Nov 15;33(14):2189-2195
pubmed: 31436610
Lancet. 2013 Jun 15;381(9883):2083-90
pubmed: 23769234
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
PLoS Med. 2017 Nov 21;14(11):e1002444
pubmed: 29161256
N Engl J Med. 2012 Aug 2;367(5):423-34
pubmed: 22784038
Int J STD AIDS. 2009 Nov;20(11):793-6
pubmed: 19875833
N Engl J Med. 2015 Feb 5;372(6):509-18
pubmed: 25651245
Clin Pharmacol Ther. 2014 Jun;95(6):617-26
pubmed: 24739446
J Int AIDS Soc. 2018 Nov;21(11):e25208
pubmed: 31291057
N Engl J Med. 2012 Aug 2;367(5):411-22
pubmed: 22784040
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
AIDS. 1999 Jul 30;13(11):1397-405
pubmed: 10449294
AIDS Res Hum Retroviruses. 2016 Jan;32(1):32-43
pubmed: 26414912
Sex Transm Dis. 2020 May;47(5):314-320
pubmed: 32187172
AIDS Behav. 2015 Dec;19(12):2204-13
pubmed: 26091706
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S122-9
pubmed: 23764623
Curr Opin Infect Dis. 2012 Feb;25(1):51-7
pubmed: 22156901
J Int AIDS Soc. 2017 Jul 25;20(1):21842
pubmed: 28741331
AIDS Patient Care STDS. 2019 Oct;33(10):434-439
pubmed: 31584857
AIDS. 2016 Jul 31;30(12):1973-83
pubmed: 27149090
AIDS. 2015 Jul 17;29(11):1277-85
pubmed: 26103095